Bactiguard and German company Schülke & Mayr GmbH (schülke) have signed an exclusive distribution agreement for Bactiguard’s range of wound care solutions to German hospitals. schülke is one of the leading global manufacturers and distributors within infection prevention and hygiene solutions.

The collaboration enables schülke to complement its comprehensive product range of antiseptic and wound care products with Bactiguard’s hypochlorous acid-based portfolio.

“We are excited about the collaboration with schülke and believe our mutual goal of preventing infections is an excellent foundation for the future. Together with schülke we aim to further develop the market for products based on hypochlorous acid – with the ultimate goal of improving patient safety and well-being”, says Peter Rådqvist, Global Head of Sales at Bactiguard.

Hypochlorous acid is an antimicrobial substance that reduces the risk of infection and promotes wound healing. It is present in the human immune system and has a favourable biocompatilibity profile, meaning it is not harming human cells. The German launch is scheduled for Q3 2021.

Headquartered outside Hamburg, Germany, schülke is a pioneer in  infection prevention and hygiene solutions with more than 130 years of experience in providing disinfection and wound care products. The company is represented in more than 100 countries and has more than 1,000 employees globally. The agreement means that schülke will distribute Bactiguard’s wound care solutions to German hospitals.

Bactiguard’s new wound care range
Bactiguard’s wound care range is a non-alcoholic, pH-neutral and water-based product line that can be used by both children and adults. The products are biocompatible, which means that they are not irritating to the skin or other tissue. They contain hypochlorous acid, the same substance as the body’s immune cells use in their defence against infectious organisms. The products neither smell strongly or sting, but effectively kill most virus, bacteria and fungi that cause infections, including the new coronavirus SARS-CoV-2.¹